Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage Cell Signaling Technology
PhosphoSitePlus
HomeAbout PhosphoSiteUsing PhosphoSiteCuration ProcessContact
NIH-logos NIGMS Logo NIAAA Logo NCI Logo NIH Logo
Curated Information Page
PubMed Id: 15657067 
This page summarizes selected information from the article referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2012,40:D261-70). To learn more about the scope of PhosphoSitePlus®, click here.
Thelemann A, et al. (2005) Phosphotyrosine signaling networks in epidermal growth factor receptor overexpressing squamous carcinoma cells. Mol Cell Proteomics 4, 356-76 15657067
Only sites from this record are displayed on this page. Click on the protein name to open the protein page, and on the RSD number to open the site page. For the complete dataset, click the download button, on the right.
Download Sites

S473-p - Akt1 (human) ▲
Orthologous residues
Akt1 (human): S473‑p, Akt1 (mouse): S473‑p, Akt1 (rat): S473‑p, Akt1 (fruit fly): S586‑p, Akt1 (cow): S473‑p
Characterization
 Methods used to characterize site in vivo:  phospho-antibody
 Relevant cell lines - cell types - tissues:  HN5 (squamous)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
IGF-1 increase
erlotinib decrease

Y727-p - EGFR (human) ▲
Orthologous residues
EGFR (human): Y727‑p, EGFR (mouse): Y729‑p, EGFR (rat): Y728‑p, EGFR (pig): Y727‑p
Characterization
 Enzymes shown to modify site in vitro: 
Type Enzyme
KINASE Src (human)

Y764-p - EGFR (human) ▲
Orthologous residues
EGFR (human): Y764‑p, EGFR (mouse): Y766‑p, EGFR (rat): Y765‑p, EGFR (pig): Y764‑p
Characterization
 Enzymes shown to modify site in vitro: 
Type Enzyme
KINASE Src (human)

Y869-p - EGFR (human) ▲
Orthologous residues
EGFR (human): Y869‑p, EGFR (mouse): Y871‑p, EGFR (rat): Y870‑p, EGFR (pig): Y869‑p
Characterization
 Methods used to characterize site in vivo:  phospho-antibody
 Relevant cell lines - cell types - tissues:  HN5 (squamous)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
erlotinib decrease

Y944-p - EGFR (human) ▲
Orthologous residues
EGFR (human): Y944‑p, EGFR (mouse): Y946‑p, EGFR (rat): Y945‑p, EGFR (pig): Y944‑p
Characterization
 Methods used to characterize site in vivo:  mass spectrometry
 Relevant cell lines - cell types - tissues:  HN5 (squamous)
 Cellular systems studied:  cell lines
 Species studied:  human

Y978-p - EGFR (human) ▲
Orthologous residues
EGFR (human): Y978‑p, EGFR (mouse): Y980‑p, EGFR (rat): Y979‑p, EGFR (pig): Y978‑p
Characterization
 Methods used to characterize site in vivo:  mass spectrometry
 Relevant cell lines - cell types - tissues:  HN5 (squamous)
 Cellular systems studied:  cell lines
 Species studied:  human

S991-p - EGFR (human) ▲
Orthologous residues
EGFR (human): S991‑p, EGFR (mouse): S993‑p, EGFR (rat): S992‑p, EGFR (pig): S991‑p
Characterization
 Methods used to characterize site in vivo:  mass spectrometry
 Relevant cell lines - cell types - tissues:  HN5 (squamous)
 Cellular systems studied:  cell lines
 Species studied:  human

Y998-p - EGFR (human) ▲
Orthologous residues
EGFR (human): Y998‑p, EGFR (mouse): Y1000‑p, EGFR (rat): Y999‑p, EGFR (pig): Y998‑p
Characterization
 Methods used to characterize site in vivo:  mass spectrometry
 Relevant cell lines - cell types - tissues:  HN5 (squamous)
 Cellular systems studied:  cell lines
 Species studied:  human

Y1016-p - EGFR (human) ▲
Orthologous residues
EGFR (human): Y1016‑p, EGFR (mouse): Y1018‑p, EGFR (rat): Y1017‑p, EGFR (pig): Y1016‑p
Characterization
 Methods used to characterize site in vivo:  phospho-antibody
 Relevant cell lines - cell types - tissues:  HN5 (squamous)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
erlotinib decrease

Y1069-p - EGFR (human) ▲
Orthologous residues
EGFR (human): Y1069‑p, EGFR (mouse): Y1069‑p, EGFR (rat): Y1068‑p, EGFR (pig): Y1068‑p
Characterization
 Methods used to characterize site in vivo:  phospho-antibody
 Relevant cell lines - cell types - tissues:  HN5 (squamous)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
erlotinib decrease

Y1092-p - EGFR (human) ▲
Orthologous residues
EGFR (human): Y1092‑p, EGFR (mouse): Y1092‑p, EGFR (rat): Y1091‑p, EGFR (pig): Y1091‑p
Characterization
 Methods used to characterize site in vivo:  phospho-antibody
 Relevant cell lines - cell types - tissues:  HN5 (squamous)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
erlotinib decrease

Y1110-p - EGFR (human) ▲
Orthologous residues
EGFR (human): Y1110‑p, EGFR (mouse): Y1110‑p, EGFR (rat): Y1109‑p, EGFR (pig): Y1109‑p
Characterization
 Methods used to characterize site in vivo:  mass spectrometry
 Relevant cell lines - cell types - tissues:  HN5 (squamous)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
erlotinib decrease

Y1138-p - EGFR (human) ▲
Orthologous residues
EGFR (human): Y1138‑p, EGFR (mouse): Y1138‑p, EGFR (rat): Y1137‑p, EGFR (pig): Y1137‑p
Characterization
 Methods used to characterize site in vivo:  mass spectrometry
 Relevant cell lines - cell types - tissues:  HN5 (squamous)
 Cellular systems studied:  cell lines
 Species studied:  human

Y1172-p - EGFR (human) ▲
Orthologous residues
EGFR (human): Y1172‑p, EGFR (mouse): Y1172‑p, EGFR (rat): Y1171‑p, EGFR (pig): Y1171‑p
Characterization
 Methods used to characterize site in vivo:  mass spectrometry
 Relevant cell lines - cell types - tissues:  HN5 (squamous)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
erlotinib decrease

Y1197-p - EGFR (human) ▲
Orthologous residues
EGFR (human): Y1197‑p, EGFR (mouse): Y1197‑p, EGFR (rat): Y1196‑p, EGFR (pig): Y1196‑p
Characterization
 Methods used to characterize site in vivo:  mass spectrometry
 Relevant cell lines - cell types - tissues:  HN5 (squamous)
 Cellular systems studied:  cell lines
 Species studied:  human

T202-p - ERK1 (human) ▲
Orthologous residues
ERK1 (human): T202‑p, ERK1 (mouse): T203‑p, ERK1 (rat): T203‑p, ERK1 (hamster): T192‑p
Characterization
 Methods used to characterize site in vivo:  phospho-antibody
 Relevant cell lines - cell types - tissues:  HN5 (squamous)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
erlotinib decrease
IGF-1 decrease

Y204-p - ERK1 (human) ▲
Orthologous residues
ERK1 (human): Y204‑p, ERK1 (mouse): Y205‑p, ERK1 (rat): Y205‑p, ERK1 (hamster): Y194‑p
Characterization
 Methods used to characterize site in vivo:  phospho-antibody
 Relevant cell lines - cell types - tissues:  HN5 (squamous)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
erlotinib decrease
IGF-1 decrease

T185-p - ERK2 (human) ▲
Orthologous residues
ERK2 (human): T185‑p, ERK2 (mouse): T183‑p, ERK2 (rat): T183‑p, ERK2 (chicken): T193‑p
Characterization
 Methods used to characterize site in vivo:  phospho-antibody
 Relevant cell lines - cell types - tissues:  HN5 (squamous)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
erlotinib decrease
IGF-1 decrease

Y187-p - ERK2 (human) ▲
Orthologous residues
ERK2 (human): Y187‑p, ERK2 (mouse): Y185‑p, ERK2 (rat): Y185‑p, ERK2 (chicken): Y195‑p
Characterization
 Methods used to characterize site in vivo:  phospho-antibody
 Relevant cell lines - cell types - tissues:  HN5 (squamous)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
erlotinib decrease
IGF-1 decrease

S9-p - GSK3B (human) ▲
Orthologous residues
GSK3B (human): S9‑p, GSK3B iso2 (human): S9‑p, GSK3B (mouse): S9‑p, GSK3B (rat): S9‑p, GSK3B (rabbit): S3‑p
Characterization
 Methods used to characterize site in vivo:  phospho-antibody
 Relevant cell lines - cell types - tissues:  HN5 (squamous)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
IGF-1 increase
erlotinib decrease

Y1112-p - HER2 (human) ▲
Orthologous residues
HER2 (human): Y1112‑p, HER2 iso2 (human): Y502‑p, HER2 (mouse): Y1113‑p, HER2 (rat): Y1114‑p
Characterization
 Methods used to characterize site in vivo:  phospho-antibody
 Relevant cell lines - cell types - tissues:  HN5 (squamous)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
erlotinib decrease

Y249-p - P130Cas (human) ▲
Orthologous residues
P130Cas (human): Y249‑p, P130Cas (mouse): Y253‑p, P130Cas (rat): Y347‑p, P130Cas iso2 (rat): Y253‑p
Characterization
 Methods used to characterize site in vivo:  mass spectrometry
 Relevant cell lines - cell types - tissues:  HN5 (squamous)
 Cellular systems studied:  cell lines
 Species studied:  human

Y306-p - P130Cas (human) ▲
Orthologous residues
P130Cas (human): Y306‑p, P130Cas (mouse): Y310‑p, P130Cas (rat): Y404‑p, P130Cas iso2 (rat): Y310‑p
Characterization
 Methods used to characterize site in vivo:  mass spectrometry
 Relevant cell lines - cell types - tissues:  HN5 (squamous)
 Cellular systems studied:  cell lines
 Species studied:  human

Y387-p - P130Cas (human) ▲
Orthologous residues
P130Cas (human): Y387‑p, P130Cas (mouse): Y391‑p, P130Cas (rat): Y485‑p, P130Cas iso2 (rat): Y391‑p
Characterization
 Methods used to characterize site in vivo:  mass spectrometry
 Relevant cell lines - cell types - tissues:  HN5 (squamous)
 Cellular systems studied:  cell lines
 Species studied:  human

T412-p - p70S6K (human) ▲
Orthologous residues
p70S6K (human): T412‑p, p70S6K iso2 (human): T389‑p, p70S6K (mouse): T412‑p, p70S6K (rat): T412‑p, p70S6K iso2 (rat): T389‑p, p70S6K (fruit fly): T398‑p
Characterization
 Methods used to characterize site in vivo:  phospho-antibody
 Relevant cell lines - cell types - tissues:  HN5 (squamous)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
IGF-1 increase
erlotinib IGF-1 inhibit treatment-induced increase

Y88-p - PXN iso2 (human) ▲
Orthologous residues
PXN (human): Y88‑p, PXN iso2 (human): Y88‑p, PXN iso3 (human): Y88‑p, PXN iso6 (human): Y95‑p, PXN (mouse): Y88‑p, PXN iso2 (mouse): Y88‑p, PXN (rat): Y88‑p, PXN (chicken): Y88‑p
Characterization
 Methods used to characterize site in vivo:  mass spectrometry, phospho-antibody
 Relevant cell lines - cell types - tissues:  HN5 (squamous)
 Cellular systems studied:  cell lines
 Species studied:  human

Y118-p - PXN iso2 (human) ▲
Orthologous residues
PXN (human): Y118‑p, PXN iso2 (human): Y118‑p, PXN iso3 (human): Y118‑p, PXN iso6 (human): Y125‑p, PXN (mouse): Y118‑p, PXN iso2 (mouse): Y118‑p, PXN (rat): Y118‑p, PXN (chicken): Y118‑p
Characterization
 Methods used to characterize site in vivo:  mass spectrometry, phospho-antibody
 Relevant cell lines - cell types - tissues:  HN5 (squamous)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
erlotinib decrease
LPA increase

Y239-p - Shc1 iso2 (human) ▲
Orthologous residues
Shc1 (human): Y349‑p, Shc1 iso2 (human): Y239‑p, Shc1 iso3 (human): Y194‑p, Shc1 iso6 (human): Y349‑p, Shc1 iso7 (human): Y239‑p, Shc1 (mouse): Y349‑p, Shc1 iso2 (mouse): Y239‑p, Shc1 iso3 (mouse): Y194‑p, Shc1 (rat): Y349‑p
Characterization
 Methods used to characterize site in vivo:  phospho-antibody
 Relevant cell lines - cell types - tissues:  HN5 (squamous)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
erlotinib decrease
IGF-1 no change compared to control
LPA no change compared to control

Y240-p - Shc1 iso2 (human) ▲
Orthologous residues
Shc1 (human): Y350‑p, Shc1 iso2 (human): Y240‑p, Shc1 iso3 (human): Y195‑p, Shc1 iso6 (human): Y350‑p, Shc1 iso7 (human): Y240‑p, Shc1 (mouse): Y350‑p, Shc1 iso2 (mouse): Y240‑p, Shc1 iso3 (mouse): Y195‑p, Shc1 (rat): Y350‑p
Characterization
 Methods used to characterize site in vivo:  phospho-antibody
 Relevant cell lines - cell types - tissues:  HN5 (squamous)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
erlotinib decrease
IGF-1 no change compared to control
LPA no change compared to control


Home  |  Curator Login With enhanced literature mining using Linguamatics I2E I2E Logo Produced by 3rd Millennium  |  Design by Digizyme
©2003-2013 Cell Signaling Technology, Inc.